Celcuity (NASDAQ:CELC – Free Report) had its target price reduced by Needham & Company LLC from $140.00 to $134.00 in a research report released on Wednesday,Benzinga reports. They currently have a buy rating on the stock.
Several other equities analysts have also issued reports on CELC. Craig Hallum reissued a “buy” rating and set a $178.00 price objective on shares of Celcuity in a report on Wednesday, July 15th. Wells Fargo & Company lowered their target price on Celcuity from $183.00 to $166.00 and set an “overweight” rating for the company in a report on Wednesday, June 3rd. Citizens Jmp reaffirmed a “market outperform” rating and set a $177.00 target price on shares of Celcuity in a research report on Monday, August 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celcuity in a research report on Tuesday, September 1st. Finally, JPMorgan Chase & Co. initiated coverage on Celcuity in a report on Thursday, September 17th. They issued an “overweight” rating and a $157.00 price target on the stock. Eleven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Celcuity currently has an average rating of “Moderate Buy” and an average price target of $154.25.
View Our Latest Research Report on Celcuity
Celcuity Stock Down 4.0%
Celcuity (NASDAQ:CELC – Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported ($1.44) EPS for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.28). As a group, research analysts anticipate that Celcuity will post -4.82 EPS for the current fiscal year.
Hedge Funds Weigh In On Celcuity
A number of large investors have recently made changes to their positions in CELC. California State Teachers Retirement System boosted its position in shares of Celcuity by 91.2% in the 1st quarter. California State Teachers Retirement System now owns 25,580 shares of the company’s stock worth $2,920,000 after purchasing an additional 12,201 shares in the last quarter. Hsbc Holdings PLC purchased a new stake in Celcuity in the fourth quarter valued at about $1,058,000. Bank of America Corp DE acquired a new stake in Celcuity in the second quarter worth about $153,928,000. Geode Capital Management LLC grew its stake in shares of Celcuity by 8.4% during the fourth quarter. Geode Capital Management LLC now owns 830,684 shares of the company’s stock worth $82,872,000 after acquiring an additional 64,213 shares during the last quarter. Finally, E Fund Management Co. Ltd. acquired a new position in shares of Celcuity during the second quarter valued at about $4,802,000. 63.33% of the stock is owned by institutional investors and hedge funds.
Celcuity Company Profile
Celcuity, Inc is a clinical-stage biotechnology company that develops functional diagnostic tests designed to help identify patients who may benefit from targeted cancer therapies. The company’s technology is intended to measure the activity of cellular signaling networks in living tumor cells, rather than relying solely on the presence or absence of individual biomarkers.
Celcuity’s proprietary CELsignia platform analyzes patient tumor samples to identify abnormal signaling activity associated with cancer growth and treatment response.
Further Reading
- Five stocks we like better than Celcuity
- AST SpaceMobile’s BlueBird Progress Comes With Several Risks Still Unresolved
- Time to Nibble on MCD Stock After it Enters Oversold Territory?
- McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal Upside
- Corning and AT&T’s $3 Billion Fiber Deal Reveals Where AI Spending Goes Next
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.
